Vitamin K2 MK-7 (MenaQ7)

Vitamin K2 MK-7 (menaquinone-7) activates vitamin K-dependent proteins like osteocalcin and matrix Gla protein through gamma-carboxylation. This mechanism supports bone mineralization and prevents arterial calcification more effectively than other vitamin K forms.

Origin & History

Vitamin K2 MK-7 is a form of vitamin K2 produced through fermentation of soybeans using Bacillus subtilis natto. It is known for its long half-life and bioavailability.

Historical & Cultural Context

Vitamin K2, particularly MK-7, is found in natto, a traditional Japanese food, and has been consumed for its health benefits for centuries.

Health Benefits

- Supports bone health by activating proteins that bind calcium, reducing fracture risk by up to 25%. - Enhances cardiovascular health by preventing arterial calcification, which is crucial for maintaining heart function. - Improves dental health by supporting bone density in the jaw, which is vital for strong teeth. - Supports brain health by reducing oxidative stress, potentially lowering the risk of neurodegenerative diseases. - Aids in blood sugar regulation by improving insulin sensitivity, which can help manage diabetes risk. - Promotes healthy aging by reducing inflammation, a key factor in age-related diseases. - Supports joint health by reducing inflammation, which can alleviate symptoms of arthritis.

How It Works

MK-7 serves as a cofactor for gamma-glutamyl carboxylase, which converts glutamic acid residues to gamma-carboxyglutamic acid in vitamin K-dependent proteins. This activates osteocalcin for calcium binding in bones and matrix Gla protein (MGP) to prevent calcium deposits in arteries. MK-7's longer half-life (72 hours) provides superior bioavailability compared to MK-4 and K1.

Scientific Research

RCTs and meta-analyses support the role of MK-7 in improving bone mineral density and reducing arterial stiffness. It is considered more effective than other forms of vitamin K.

Clinical Summary

A 3-year randomized controlled trial of 244 postmenopausal women found 180 mcg daily MK-7 reduced bone mineral density loss and improved bone strength by 25%. Cardiovascular studies show MK-7 supplementation (180-360 mcg daily) reduces arterial stiffness by 6-12% over 12 weeks. Meta-analyses indicate moderate evidence for bone benefits but limited long-term cardiovascular data. Most studies use the patented MenaQ7 form with consistent bioavailability.

Nutritional Profile

Vitamin K2 MK-7 (MenaQ7) is a bioactive form of menaquinone-7, a fat-soluble vitamin with no caloric macronutrient contribution. Active compound: menaquinone-7 (MK-7) at typical supplemental doses of 45–360 mcg per serving, with 100–200 mcg being the most clinically studied range. MenaQ7 is a patented, natural-source MK-7 derived from fermented chickpeas (Cicer arietinum) via Bacillus subtilis natto fermentation. Key bioactive compound: all-trans MK-7 isomer, which is the biologically active configuration; MenaQ7 standardizes for >97% all-trans content, distinguishing it from synthetic K2 sources that may contain inactive cis-isomers. Molecular weight: 649.0 g/mol. No protein, carbohydrate, fiber, or fat content inherent to the isolated ingredient itself. Micronutrient classification: fat-soluble vitamin (K family). Bioavailability notes: MK-7 has significantly superior bioavailability compared to MK-4 and vitamin K1 (phylloquinone) due to its longer side chain (7 isoprene units), resulting in a plasma half-life of approximately 72 hours versus 1–2 hours for K1. Absorption requires dietary fat co-ingestion; peak plasma concentration reached within 4–6 hours post-ingestion. MenaQ7 specifically demonstrates consistent carboxylation of osteocalcin and Matrix Gla Protein (MGP) at doses as low as 90 mcg/day. Serum binding occurs primarily via LDL and HDL lipoproteins. No known interference with warfarin at doses below 50 mcg in most individuals, though caution is advised.

Preparation & Dosage

Typical dosages range from 90 to 120 mcg per day. Consult a healthcare provider before use.

Synergy & Pairings

Vitamin D3, Calcium, Magnesium

Safety & Interactions

MK-7 is generally well-tolerated with no serious adverse effects reported in clinical trials up to 360 mcg daily. It may enhance warfarin's anticoagulant effects, requiring INR monitoring in patients taking blood thinners. Mild gastrointestinal symptoms occur in less than 5% of users. Safety during pregnancy and lactation is not established, though no teratogenic effects are known.